MaxCyte MXCT Stock
MaxCyte Price Chart
MaxCyte MXCT Financial and Trading Overview
| MaxCyte stock price | 1.43 USD |
| Previous Close | 1.33 USD |
| Open | 1.33 USD |
| Bid | 1.05 USD x 200 |
| Ask | 1.71 USD x 200 |
| Day's Range | 1.33 - 1.48 USD |
| 52 Week Range | 0.64 - 2.37 USD |
| Volume | 2.11M USD |
| Avg. Volume | 1.2M USD |
| Market Cap | 147.83M USD |
| Beta (5Y Monthly) | 1.663 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.11 USD |
MXCT Valuation Measures
| Enterprise Value | 58.46M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.862362 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.578558 |
| Price/Book (mrq) | 0.8806637 |
| Enterprise Value/Revenue | 1.811 |
| Enterprise Value/EBITDA | -1.711 |
Trading Information
MaxCyte Stock Price History
| Beta (5Y Monthly) | 1.663 |
| 52-Week Change | -34.59% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 2.37 USD |
| 52 Week Low | 0.64 USD |
| 50-Day Moving Average | 1.11 USD |
| 200-Day Moving Average | 1.2 USD |
MXCT Share Statistics
| Avg. Volume (3 month) | 1.2M USD |
| Avg. Daily Volume (10-Days) | 1.11M USD |
| Shares Outstanding | 107.12M |
| Float | 97.63M |
| Short Ratio | 1 |
| % Held by Insiders | 1.59% |
| % Held by Institutions | 68.18% |
| Shares Short | 1.52M |
| Short % of Float | 1.42% |
| Short % of Shares Outstanding | 1.40% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -121.16% |
| Operating Margin (ttm) | -64.087% |
| Gross Margin | 80.50% |
| EBITDA Margin | -105.80% |
Management Effectiveness
| Return on Assets (ttm) | -11.31% |
| Return on Equity (ttm) | -21.30% |
Income Statement
| Revenue (ttm) | 32.29M USD |
| Revenue Per Share (ttm) | 0.3 USD |
| Quarterly Revenue Growth (yoy) | -7.099% |
| Gross Profit (ttm) | 25.99M USD |
| EBITDA | -34161000 USD |
| Net Income Avi to Common (ttm) | -39119000 USD |
| Diluted EPS (ttm) | -0.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 106.85M USD |
| Total Cash Per Share (mrq) | 1 USD |
| Total Debt (mrq) | 17.49M USD |
| Total Debt/Equity (mrq) | 10.42 USD |
| Current Ratio (mrq) | 12.038 |
| Book Value Per Share (mrq) | 1.567 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28168000 USD |
| Levered Free Cash Flow (ttm) | -14128000 USD |
Profile of MaxCyte
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9713 Key West Avenue |
| ZIP | 20850 |
| Phone | 301 944 1700 |
| Website | https://www.maxcyte.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 91 |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Q&A For MaxCyte Stock
What is a current MXCT stock price?
MaxCyte MXCT stock price today per share is 1.43 USD.
How to purchase MaxCyte stock?
You can buy MXCT shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MaxCyte?
The stock symbol or ticker of MaxCyte is MXCT.
Which industry does the MaxCyte company belong to?
The MaxCyte industry is Medical Devices.
How many shares does MaxCyte have in circulation?
The max supply of MaxCyte shares is 107.12M.
What is MaxCyte Price to Earnings Ratio (PE Ratio)?
MaxCyte PE Ratio is now.
What was MaxCyte earnings per share over the trailing 12 months (TTM)?
MaxCyte EPS is -0.36 USD over the trailing 12 months.
Which sector does the MaxCyte company belong to?
The MaxCyte sector is Healthcare.
MaxCyte MXCT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26217.15 USD — |
+0.42
|
5B USD — | 26041.13 USD — | 26316.81 USD — | — - | 5B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12864.72 USD — |
+0.39
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6550.65 USD — |
+0.52
|
— — | 6454.97 USD — | 6560.7 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1250.32 USD — |
+0.73
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}